The popularity of copyright’s blockbuster initially sparked a boom for the drug industry, however recent changes present a murky scenario for shareholders. Lower-cost alternatives are eroding earnings, and continued litigation add further difficulty to the equation. While certain companies might still gain from adjacent services, the broader traj